BioSpace News Archive

Tonix Pharmaceuticals Holding Corp. announced that in the currently-enrolling Phase 3 study of Tonmya®* for the treatment of posttraumatic stress disorder, the timing of the primary endpoint analysis has been changed from Week 4 to Week 12 and the Company plans to add an interim analysis that allows for a potential sample size adjustment, based on guidance from its recent Breakthrough Therapy Type B Clinical Guidance meeting with the U.S. Food and Drug Administration.

FibroGen, Inc., announced that financial results for the third quarter 2019 will be released after market on Monday, November 11, 2019.

Stryker announced a definitive agreement to acquire all of the issued and outstanding ordinary shares of Wright Medical Group N.V. for $30.75 per share, or a total equity value of approximately $4.0 billion and a total enterprise value of approximately $5.4 billion Wright Medical, which was founded in 1950, is a global medical device company focused on extremities and biologics.

Development of PEGPH20 to be Discontinued Immediately

Children and adolescents living with type 1 diabetes achieved comparable reduction in average blood sugar and similar risk of low blood sugar events with Toujeo® 300 Units/mL compared to insulin glargine 100 Units/mL, according to results presented at the International Society for Pediatric and Adolescent Diabetes 45th Annual Conference in Boston, Massachusetts.

Correvio Pharma Corp. announced that the U.S. Food and Drug Administration will hold a Cardiovascular and Renal Drugs Advisory Committee meeting in connection with its review of the pending New Drug Application for Brinavess™ The meeting will be held on December 10, 2019 from 8:00 a.m. to 5:00 p.m. ET.

HBM4003 is the First Fully Human Heavy Chain Only Antibody Ever to Enter Human Trials

Based on encouraging Phase II results, patients with underlying CPB7 cirrhosis who lack a viable treatment option are now provided Namodenoson

Kraig Biocraft Laboratories, Inc., the leading developer of spider silk based fibers, announced that its operations team at its Vietnamese subsidiary, Prodigy Textiles, has completed rearing the Company’s first batch of production silkworms.

Epizyme, Inc., a late-stage biopharmaceutical company developing novel epigenetic therapies, announced funding agreements with Royalty Pharma and its affiliate Pharmakon Advisors that, in aggregate, could bring in up to $270 million in capital, significantly strengthening Epizyme’s financial position and extending its operating runway into at least 2022.